Article Information
History
- March 10, 2025.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Elliot Outland1,#,
- Yi Xin1,2,#,
- Alyson L. Dickson3,
- Xue Zhong4,
- Gul Karakoc3,
- Sevim Kilic3,
- Lan Jiang3,
- Nancy J. Cox4,
- Wei-Qi Wei1,2,
- C. Michael Stein3,5 and
- QiPing Feng1,3,4,*
- 1Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN
- 2Department of Computer Science, Vanderbilt University, Nashville, TN
- 3Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
- 4Vanderbilt Genetics Institute, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
- 5Department of Pharmacology, Vanderbilt University, Nashville, TN
- ↵*Corresponding Author: QiPing Feng, PhD, Vanderbilt University Medical Center, 2222 Pierce Ave., Nashville, TN 37232, USA (Tel:615-936-3551, qiping.feng{at}vumc.org)
↵# The authors contributed equally. Word count: 3606
Posted March 10, 2025.
Using Mendelian randomization to assess long-term pleiotropic effects of potential novel triglyceride-lowering medications
